Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

nuzefatide pevedotin

A bicyclic peptide targeting Ephrin receptor A2 (EphA2) and conjugated, through an inert sarcosine spacer chain and a valine-citrulline cleavable linker, to the cytotoxic agent monomethyl auristatin E (MMAE), an auristatin derivative and a potent inhibitor of microtubule polymerization, with potential antineoplastic activity. Upon administration, nuzefatide pevedotin targets and binds to EphA2-expressing tumor cells. After internalization and enzymatic cleavage of the immunoconjugate within the tumor cell cytosol, free MMAE binds to tubulin and inhibits its polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. The cell-surface receptor EphA2, a member of the ephrin family of receptor tyrosine kinases (RTKs) involved in mammalian development, is overexpressed by a variety of different cancer cell types. EphA2 expression is associated with poor prognosis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:bicycle BT5528
bicycle toxin conjugate-targeting EphA2 BT5528
bicyclic peptide conjugate BT5528
BTC BT5528
EphA2-targeting Bicycle Toxin Conjugate BT5528
EphA2-targeting BTC BT5528
EphA2-targeting-MMAE bicycle toxin BT5528
Code name:BT 5528
BT-5528
BT5528
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search